- Home
- VEL vs CTMX Comparison
VEL vs CTMX Comparison
Compare VEL & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEL
- CTMX
- Stock Information
- Founded
- VEL 2004
- CTMX 2008
- Country
- VEL United States
- CTMX United States
- Employees
- VEL N/A
- CTMX N/A
- Industry
- VEL Finance: Consumer Services
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- VEL Finance
- CTMX Health Care
- Exchange
- VEL Nasdaq
- CTMX Nasdaq
- Market Cap
- VEL 602.1M
- CTMX 596.2M
- IPO Year
- VEL 2020
- CTMX 2015
- Fundamental
- Price
- VEL $18.38
- CTMX $3.33
- Analyst Decision
- VEL Strong Buy
- CTMX Strong Buy
- Analyst Count
- VEL 3
- CTMX 5
- Target Price
- VEL $21.67
- CTMX $5.80
- AVG Volume (30 Days)
- VEL 69.4K
- CTMX 2.8M
- Earning Date
- VEL 11-06-2025
- CTMX 11-06-2025
- Dividend Yield
- VEL N/A
- CTMX N/A
- EPS Growth
- VEL 26.95
- CTMX 263.20
- EPS
- VEL 2.22
- CTMX 0.49
- Revenue
- VEL $195,592,000.00
- CTMX $141,100,000.00
- Revenue This Year
- VEL $3.99
- CTMX N/A
- Revenue Next Year
- VEL $29.69
- CTMX N/A
- P/E Ratio
- VEL $8.29
- CTMX $6.81
- Revenue Growth
- VEL 44.29
- CTMX 18.01
- 52 Week Low
- VEL $16.12
- CTMX $0.40
- 52 Week High
- VEL $20.98
- CTMX $3.91
- Technical
- Relative Strength Index (RSI)
- VEL 50.99
- CTMX 55.85
- Support Level
- VEL $17.74
- CTMX $3.21
- Resistance Level
- VEL $18.73
- CTMX $3.50
- Average True Range (ATR)
- VEL 0.36
- CTMX 0.24
- MACD
- VEL 0.04
- CTMX -0.06
- Stochastic Oscillator
- VEL 54.70
- CTMX 21.62
About VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.